Find information and resources for current and returning patients. Learn about clinical trials at MD Anderson and search our database for open studies. The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

Your gift will help support our mission to end cancer and make a difference in the lives of our patients. Our personalized portal helps you refer your patients and communicate with their MD Anderson care team. As part of our mission to eliminate cancer, MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

Choose from 12 allied health programs at School of Health Professions. Learn about our graduate medical education residency and fellowship opportunities.

We recently asked Stephanie Watowich, Ph. Inflammation is a local or systematic reaction from the cells in our immune system, but research has shown that there are different types of inflammation and that cells from other parts of the body are also involved. It can be either, depending on how long the inflammation lasts.

Truth: Inflammation can contribute to the development of certain cancers. However, inflammation has been linked to the spread of ca ncer to other parts of the body. At the same time, there are types of inflammation that help kill tumors. For example, immunotherapies can capitalize on inflammatory processes to attack and treat cancer.

Request an appointment at MD Anderson online or by calling We have to understand inflammation in its context to understand if it's helping or hurting. Other causes of chronic inflammation can include obesity , smoking , stress , lack of exercise , exposure to secondhand smoke and diet choices.

And worse, chronic inflammation often shows no symptoms. The good news is you can reduce chronic inflammation and lower your cancer risks. Plant foods are the only foods that contain anti-inflammatory phytonutrients. Plus, they are high in the antioxidants and fiber your body needs to reduce your cancer risk.

Recent research suggests that fiber also may lower levels of C-reactive protein CRP , a protein in the blood that signals inflammation. The American Institute for Cancer Research recommends filling at least two-thirds of your plate with non-starchy vegetables, whole grains and fruit.

Fill the remaining one-third or less with lean protein or plant-based protein. Processed foods are lower in nutrients and higher in refined sugars, flours and unhealthy fats. Eating the right dietary fats is important for reducing inflammation.

Omega-3 fatty acids can help protect your body from chronic inflammation. On the other hand, omega-6 fatty acids increase inflammation. Eating too much red meat , like pork, beef, lamb, deer and buffalo, can increase your cancer risk. Try to limit red meat to 18 oz. or less a week.

Crawfofd suggests replacing red meat with these high-protein foods to help reduce chronic inflammation. Fermented foods, also known as probiotics , can help reduce inflammation.

To get the most health perks, eat at least one small serving of a fermented food each day. My Chart. Donate Today. Request an Appointment Request an Appointment New Patients Current Patients Referring Physicians. Manage Your Risk Manage Your Risk Manage Your Risk Home Tobacco Control Diet Body Weight Physical Activity Skin Safety HPV Hepatitis.

Family History Family History Family History Home Genetic Testing Hereditary Cancer Syndromes Genetic Counseling and Testing FAQs. Donate Donate Donate Home Raise Money Honor Loved Ones Create Your Legacy Endowments Caring Fund Matching Gifts.

Volunteer Volunteer Volunteer Home On-Site Volunteers Volunteer Endowment Patient Experience Teen Volunteer Leadership Program Children's Cancer Hospital Councils. Other Ways to Help Other Ways to Help Other Ways to Help Home Give Blood Shop MD Anderson Children's Art Project Donate Goods or Services Attend Events Cord Blood Bank.

Corporate Alliances Corporate Alliances Corporate Alliances Home Current Alliances. For Physicians. Acetylsalicylic acid ASA , also known as aspirin, is one of the most widely used drugs in the world, particularly for prevention of cardiovascular diseases The strongest beneficial effect has been found in esophageal adenocarcinoma, colorectal and stomach cancers and a smaller effect was observed in breast, lung, and prostate cancers No benefit was found for hematopoietic malignancies, pancreatic and endometrial cancer Increased expression of Cox2 and its major metabolite prostaglandin E2 PGE2 has been observed in many different types of cancer in which they enhance angiogenesis, apoptosis resistance, tumor growth, and metastasis Recent studies show that epigenetic modifications may also be involved in the chemopreventive actions of ASA, leading to suppressed histone deacetylase HDAC activity and increased H3K27 acetylation which results in reduced expression of iNos , Tnf , and Il6 Nevertheless, long-term NSAID administration can result in side effects including renal failure and gastrointestinal GI symptoms including mucosal lesions, bleeding, peptic ulcer, and intestinal inflammation which causes perforation and strictures in small and large intestines Such adverse effects may actually increase cancer risk.

Furthermore, NSAID intake increases the risk of deep vein thrombosis and its potentially life-threatening complications of pulmonary embolism, myocardial infarction, and stroke Several selective COX2 inhibitors that impair tumor growth and metastasis celecoxib, rofecoxib, valdecoxib, apricoxib, etoricoxib, and lumiracoxib were approved for marketing, but later withdrawn mostly due to increased risk of thromboembolic events.

Celecoxib is the only selective COX2 inhibitor that is still available in the United States and Europe Combining COX2 inhibitors with 5-LOX inhibitors can block synthesis of both prostaglandins and leukotrienes, resulting in reduced gastrointestinal toxicity In this context, the herbal medicines including the natural hydro-alcoholic extract of Cordia myxa fruit is considerably effective in treatment of acute inflammation in rats, and the active ingredients of its seeds, such as alpha-amyrins, have anticancer and anti-inflammatory activities by inhibiting COX2 and 5-LOX Corticosteroids, most commonly used as anti-emetic drugs that prevent chemotherapy-induced nausea and vomiting, are the most effective anti-inflammatory drugs for many chronic inflammatory diseases and were shown to have anticancer activity For example, pretreatment with dexamethasone increased effectiveness of chemotherapy in xenograft or syngeneic experimental tumor models of glioma, breast, lung, and colon cancers Dietary consumption of DEX has a chemopreventive effect in mice exposed to tobacco smoke, leading to decreased lung tumor incidence Recent studies had shown that DEX in combination with carfilzomib and lenalidomide, significantly improved progression-free survival of patients with relapsed multiple myeloma ref.

gov number, NCT In contrast high-dose inhaled ICS and oral corticosteroid OCS treatment, used to reduce local and systemic inflammation in patients with asthma and chronic obstructive pulmonary disease COPD , was found to increase the risk of squamous lung cell carcinoma in men Statins are a family of drugs that lower blood cholesterol concentration by blocking the 3-hydroxymethylglutaryl coenzyme A HMG-CoA reductase, which results in impaired cholesterol synthesis and by enhancing cholesterol clearance from the circulation In addition to its cholesterol-lowering effects statins also have anti-inflammatory properties 87 , which makes them powerful agents in prevention of atherosclerosis and resulting in life-threatening conditions, heart attack, and stroke.

Statins are able of reducing systemic proinflammatory cytokine and C-reactive protein CRP levels and macrophage infiltration 88, By exerting anti-inflammatory and other effects, statins also reduce the risk of development of several cancer types including colorectal cancer, HCC, and breast cancer 90— Metformin, a drug used for treatment of type 2 diabetes mellitus, was found to be associated with decreased incidence of a variety of cancer types including colon, breast, lung, prostate, ovarian, and pancreatic cancers Its antineoplastic effect is mediated through activation of the AMPK pathway, which counteracts the protumorigenic effect of hyperinsulinemia, the reduction of systemic glucose concentration, which counteracts Warburg effect and through its anti-inflammatory properties TAMs can generally promote cancer cell proliferation, stimulate tumor angiogenesis and extracellular matrix breakdown, suppress antitumor immune responses, and enhance tumor invasion and metastasis Their recruitment into the tumor microenvironment from the blood stream is primarily regulated by cytokines, chemokines, and growth factors that are derived from tumor and stromal cells.

The tumor-derived C-C chemokine ligand 2 CCL2 , acting via its receptor C-C chemokine receptor 2 CCR2 , is a direct mediator of monocyte recruitment into primary tumors TAMs are classified as either classically activated M1 or alternatively activated M2 macrophages The T H 1 cytokine IFNγ and LPS are the major inducers of the M1 phenotype, whereas T H 2 cytokines, such as IL4, IL10, and IL, stimulate M2 polarization During the course of tumor development, the TAM phenotype is modulated by different factors in the tumor microenvironment and it changes from the M1 to the M2 phenotype, which is claimed to have stronger tumor-promoting properties M2 macrophages are associated with poor prognosis in many different cancer types and can promote cell-cycle progression and angiogenesis while inhibiting apoptosis In fact, M1 and M2 characteristics often coexist within the same cell, and there is a broad variety of macrophage subtypes between the M1 and M2 poles Furthermore, the most potent tumor-promoting cytokines, such as IL6, TNF, IL1, and IL23 are considered as M1 cytokines Because of their important role in linking inflammation and cancer, the targeting of TAM recruitment and differentiation provides an opportunity for cancer prevention and treatment.

Depletion of CCL2 with a neutralizing antibody prevents monocyte recruitment to the primary tumor site and reduces pulmonary metastasis of human breast cancer cells A human anti-CCL2 antibody, CNTO , showed preliminary antitumor activity in patients while being well tolerated Blockade of CCR2 with small-molecule antagonist showed antitumor activity in pancreatic cancer in animal studies and this strategy is now being tested in clinical trials ClinicalTrials.

gov Identifier: NCT Trabectedin, a DNA-binding drug approved in Europe for the treatment of soft tissue sarcoma, has been shown to selectively deplete mononuclear phagocytes in vivo , including TAMs Rapidly growing tumors often outgrow their blood supply, which results in formation of hypoxic areas with TAM accumulation Binding of semaphorin 3A to its receptor neuropilin-1 Nrp1 recruits TAMs toward the hypoxic area where they adopt the M2 phenotype and release proangiogenic factors Inhibition of Nrp1 reduced TAM migration and prevented their phenotypic switch to M2-like immunosuppressive cells with angiogenic activity making it an interesting target for anticancer therapy.

Several therapies convert macrophages from an M2 to an M1 phenotype Tasquinimod is a small-molecule compound that reduces the immunosuppressive potential of the tumor microenvironment A recent study demonstrated its ability to induce a shift of imunosuppresive M2 to proinflammatory M1 macrophages in colon and breast cancer models Colony-stimulating factor 1 CSF-1 and its receptor, CSF-1R, mediate migration, differentiation, and survival of macrophages Treatment with anti-CSF-1R antibody resulted in TAM depletion in several tumor types in vitro and in vivo and a clinical benefit for patients with diffuse-type giant cell tumors TAMs express significant amounts of COX2 and the selective COX2 inhibitor celecoxib was shown to switch their phenotypic characteristics from M2- to M1-like, which was followed by a reduction in number of colon polyps in an animal study on colon cancer Recent studies had shown that decreasing TAM survival, by the targeting folate receptor-β FR-β , a marker for the M2-polarized phenotype, is another promising strategy against cancer, in an experimental glioma model NF-κB and STAT3 are 2 critical transcription factors that are activated in many types of cancers 8, , The STAT proteins family, which includes 7 members, regulates multiple processes related to cellular proliferation, survival, and angiogenesis Among the different STATs, the one most important for cancer is STAT3, whose activity is stimulated by IL6, IL11 and other members of their cytokine family, as well as different growth factors In HCC and liver adenomas, STAT3 activity is stimulated by various oncogenic mutations , but more often than not, STAT3 is maintained in an activated state due to elevated production of IL6 and other cytokines STAT3 signaling also has important roles in tumor microenvironment where it promotes ILmediated protumorigenic immune responses while inhibiting expression of antitumorigenic IL12 Inhibition or ablation of STAT3 can mediate tumor regression Therefore, inhibition of STAT3 provides a rational strategy to block carcinogenesis at an early stage and induce regression of established tumors.

There are 3 major approaches to inhibit STAT3 signaling: inhibition of tyrosine kinases, such as JAK1 and 2, that are responsible for STAT3 activation AG- , ruxolitinib, etc.

Among tyrosine kinase inhibitors some are rather specific for JAK2 family members, whereas others inhibit several different kinases that lead to STAT3 activation Currently, these drugs are being evaluated as neoadjuvants in several types of cancer, including pediatric refractory or recurrent solid tumors, hematologic malignancies , pancreatic adenocarcinoma, triple-negative breast cancer, urothelial cancer, multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome lymphoma ClinicalTrials.

gov number, NCT , endometrial cancer, gastric cancer, head and neck squamous cell carcinoma, melanoma, microsatellite-unstable colorectal cancer, non—small cell lung cancer ClinicalTrials. gov number, NCT, NCT , and estrogen receptor—positive invasive metastatic breast cancer ClinicalTrials.

Despite their clinical approval and marketing in myelofibrosis and rheumatoid arthritis, JAK inhibitors exert rather serious side effects including anemia, thromobocytopenia, headaches, nausea, and neurotoxicity However, more selective inhibitors with fewer side effects are currently being developed.

Yet, it is doubtful whether such agents will ever find use in cancer prevention. Targeting STAT3 proinflammatory pathway. Schematic representation of the major targetable events during STAT3 activation, and the corresponding compounds with cancer-preventive properties.

The NF-κB pathway is constitutively activated in many cancers, both in malignant cells and in components of the tumor microenvironment NF-κB activation in malignant cells increases the expression of genes, whose products promote cell survival and proliferation, whereas NF-κB activation in components of the tumor stroma increases expression of inflammatory cytokines and growth factors 8, NF-κB activation also promotes epithelial-to-mesenchymal transition EMT and tumor angiogenesis Although NF-κB activation plays a major role in the induction of inflammation, long-term and extensive inhibition of NF-κB can result in profound inflammation due to enhanced production of IL1β upon activation of the NLRP3 inflammasome This can result in severe neutrophilia , a serious condition that led to termination of any further clinical development.

Nonetheless, the cancer prevention literature is full of reports using natural anti-inflammatory agents, including curcumin, resveratrol, ursolic acid, capsaicin, silibinin, silymarin, guggulsterone, and plumbagin, all of which are claimed to act as NF-κB inhibitors — Most likely, however, these are rather mild and nonspecific NF-κB inhibitors, most of which affect multiple targets, including STAT3.

Because of their rather mild effects, such agents, many of which are used as nutritional supplements, can be used in cancer prevention , but it is doubtful whether they will ever find use as anticancer drugs.

The major problem associated with NF-κB inhibition is enhanced activation of the NLRP3 inflammasome The inflammasome is a multimeric complex consisting of the intracellular Nod-like receptors NLR and the adaptor protein ASC that serves as a platform for activation of caspase-1 Inflammasomes have a crucial role in host defense against infection as well as various autoinflammatory conditions Upon NLR oligomerization and subsequent interaction between the adaptor protein ASC and the CARD domain, caspase-1—mediated processing results in production of the proinflammatory cytokines IL1β and IL18 or a rapid inflammatory form of cell death called pyroptosis NF-κB is the first signal that primes NLR and pro-IL1β expression , but persistent NF-κB activation is also responsible for dysregulated NLRP3 inflammasome activation by inducing the mitophagic clearance of damaged mitochondria The role of NLR-containing inflammasomes in mediating cancer initiation and progression by creating a proinflammatory microenvironment for inducing malignant transformation and suppression of local immunity caused by NK or T cells open the way for novel strategy in cancer prevention.

Between the 22 NLRs in the human and the 34 NLRs in the mouse genome, NLRP3 NLR family, pyrin domain containing 3 is the best characterized.

The NLRP3 inflammasome plays an important role in several inflammatory disorders including IBD , and its activation is negatively regulated by selective mitochondrial autophagy mitophagy; ref. During tumorigenesis, IL6 has served detrimental effects including stimulation of cell survival and proliferation, regulation of stem cell renewal, and induction of angiogenesis.

A humanized anti-IL6 receptor monoclonal antibody toclizumab is an FDA-approved immunosuppressive drug that blocks IL6 signaling. It is used in the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis Chimeric monoclonal antibody siltuximab that binds IL6 showed good tolerance in patients with cancer in a phase I clinical trial and is currently investigated for the treatment of several tumor types including prostate cancer and metastatic renal cell cancer Long-term treatment with anti—IL6-blocking antibody was associated with very few side effects in a mouse model of pancreatic cancer prevention Thus, IL6 emerges as a promising potential target for cancer prevention.

The proinflammatory chemokine IL8 and its receptors CXCR1 and CXCR2 were also linked to cancer and inflammation Another proinflammatory cytokine with reported role in promoting tumorigenesis is IL17A TGFβ and IL6 are needed for the differentiation and IL23 for the maintenance of T H 17 cells that produce IL17A.

Antibodies against IL17A ixekizumab and secukinumab and its receptor IL17AR brodalumab are in clinical trials for chronic inflammatory conditions and autoimmune diseases and an anti-IL23 antibody ustekinumab was FDA-approved for the treatment of psoriatic arthritis However, preventive application of such drugs should take in account reported antitumor effects of IL17 in established tumors as well as its role in autoimmunity.

Vaccines that protect against certain viral infection play important role in cancer prevention. For instance, hepatitis B virus HBV is a major cause of HCC whose impact has been dramatically reduced in all countries due to massive vaccination efforts The most effective way to prevent HBV infection and reduce HCC development is vaccination The prophylactic vaccine that is currently in use is generated by recombinant DNA technology and contains HBsAg protein and adjuvants.

For patients who have already been infected by HBV and developed chronic hepatitis, secondary prevention becomes more important. Currently, antiviral drugs used in patients with chronic hepatitis B include the immunomodulator PEGylated IFNα and oral nucleos t ide analogues IFNs activate various IRF family members that regulate transcription of numerous targets, including genes involved in control of viral mRNA translation or degradation However, the mechanism of IFNα-mediated cell protection against viral infection is not fully understood.

In addition to HBV, hepatitis C virus HCV is another important cause of HCC, against which there is no preventive vaccine However, the recent development of highly effective anti-HCV drugs will lead to major decrease in HCV-induced HCC Human papilloma virus HPV is a major cause of cervical intraepithelial neoplasia that can progress to invasive cervical cancer Recently, we have witnessed the development of an effective HPV vaccine that if properly distributed amongst young adults will lead to a major decrease in the impact of cervical and other urogenital cancers.

In summary, vaccination against cancer-causing viruses is one of the most effective and economical ways to reduce the toll of several inflammation-related cancers.

Todoric was supported by the Erwin Schroedinger Fellowship from the Austrian Science Fund J and Univ. Müller Fellowship from the Austrian Association for Laboratory Medicine and Clinical Chemistry ÖGLMKC and the Austrian Program for Advanced Research and Technology of the Austrian Academy of Sciences.

Antonucci was supported by the International Cancer Research Fellowship iCARE , AIRC Associazione Italiana per la ricerca sul cancro co-founded by the European Union. Karin was supported by grants from the NIH grants CA and the Lustgarten Foundation RFP-B who holds the Ben and Wanda Hildyard Chair for Mitochondrial and Metabolic Diseases and is an American Cancer Society Research Professor.

Sign In or Create an Account. Search Dropdown Menu. header search search input Search input auto suggest. Advanced Search. User Tools Dropdown. Sign In. Toggle Menu Menu About The Journal Editorial Board AACR Journals Subscriptions Permissions and Reprints Articles Online First Issues Meeting Abstracts PreCancer Atlas Collection: From Biology to Cancer Interception Collection: Biology of Susceptibility and Premalignancy Collection: E-Cigarettes Collection: Must-Read Articles Collection: Editors' Picks COVID 'Best 'Of' Collection For Authors Information for Authors Author Services Outstanding Journal Article Award Best of: Author Profiles Submit Alerts News Cancer Hallmarks Webinars.

Skip Nav Destination Close navigation menu Article navigation. Volume 9, Issue

On the other hand, omega-6 fatty acids increase inflammation. Eating too much red meat , like pork, beef, lamb, deer and buffalo, can increase your cancer risk. Try to limit red meat to 18 oz. or less a week. Crawfofd suggests replacing red meat with these high-protein foods to help reduce chronic inflammation.

Fermented foods, also known as probiotics , can help reduce inflammation. To get the most health perks, eat at least one small serving of a fermented food each day. My Chart.

Donate Today. Request an Appointment Request an Appointment New Patients Current Patients Referring Physicians. Manage Your Risk Manage Your Risk Manage Your Risk Home Tobacco Control Diet Body Weight Physical Activity Skin Safety HPV Hepatitis.

Family History Family History Family History Home Genetic Testing Hereditary Cancer Syndromes Genetic Counseling and Testing FAQs. Donate Donate Donate Home Raise Money Honor Loved Ones Create Your Legacy Endowments Caring Fund Matching Gifts.

Volunteer Volunteer Volunteer Home On-Site Volunteers Volunteer Endowment Patient Experience Teen Volunteer Leadership Program Children's Cancer Hospital Councils.

Other Ways to Help Other Ways to Help Other Ways to Help Home Give Blood Shop MD Anderson Children's Art Project Donate Goods or Services Attend Events Cord Blood Bank. Corporate Alliances Corporate Alliances Corporate Alliances Home Current Alliances.

For Physicians. Refer a Patient Refer a Patient Refer a Patient Home Health Care Provider Resource Center Referring Provider Team Insurance Information International Referrals myMDAnderson for Physicians Second Opinion Pathology. Clinical Trials Clinical Trials Clinical Trials Home. Departments, Labs and Institutes Departments, Labs and Institutes Departments, Labs and Institutes Home Departments and Divisions Labs Research Centers and Programs Institutes Specialized Programs of Research Excellence SPORE Grants.

Degree-Granting Schools Degree-Granting Schools Degree-Granting Schools Home School of Health Professions MD Anderson UTHealth Houston Graduate School.

Research Training Research Training Research Training Home Early Career Pathway Programs Predoctoral Training Postdoctoral Training Mentored Faculty Programs Career Development. Outreach Programs Outreach Programs Outreach Programs Home Project ECHO Observer Programs Comparative Effectiveness Training CERTaIN.

May Inflammation and cancer: Why your diet is important. Next Article. May : Inflammation and cancer: Why your diet is important. What does inflammation have to do with cancer?

Add more plant foods to your diet Plant foods are the only foods that contain anti-inflammatory phytonutrients. Skip highly processed foods, like fast food, packaged and instant foods. Steer clear of processed meats , like deli-meats, bacon, sausage, hotdogs and pepperoni.

Avoid sodas and sports drinks. Balance fatty acids Eating the right dietary fats is important for reducing inflammation. Eat foods high in omega-3 fatty acids, like salmon, tuna, halibut, flaxseeds, chia seeds, walnuts, pecans and avocado.

Use oils high in omega-3, such as olive oil and canola oil. Avoid or limit oils high in omega-6, such as corn, sunflower, peanut and soybean oils.

Read the ingredients on packaged foods. Limit foods made with refined vegetable oils high in omega Limit red meat Eating too much red meat , like pork, beef, lamb, deer and buffalo, can increase your cancer risk.

Choose animal proteins like skinless chicken, turkey and fish. Replace animal proteins with plant proteins, like beans and lentils, at some meals. Choose meat, milk, cheese and eggs from pasture-raised and hormone-free animals. Eat more fermented foods Fermented foods, also known as probiotics , can help reduce inflammation.

Autophagy 13 , — Wang, A. Opposing effects of fasting metabolism on tissue tolerance in bacterial and viral inflammation. Cell , — e This paper investigates voluntary fasting as a physiological component of the sickness response elicited by bacterial infection.

Dror, E. Postprandial macrophage-derived IL-1β stimulates insulin, and both synergistically promote glucose disposal and inflammation. van Niekerk, G. Autophagy: a free meal in sickness-associated anorexia. Autophagy 12 , — Puchalska, P.

Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Youm, Y. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease.

This paper demonstrates that fasting-induced production of β-hydroxybutyrate limits inflammation by hindering NRLP3 inflammasome activation. Hopkins, B. Obesity and cancer mechanisms: cancer metabolism.

This excellent position paper describes the major negative effects of obesity on oncogenesis and cancer progression. Moore, L. Metabolic health reduces risk of obesity-related cancer in Framingham Study adults.

Cancer Epidemiol. Biomarkers Prev. Systemic correlates of white adipose tissue inflammation in early-stage breast cancer. Kolb, R. Obesity-associated NLRC4 inflammasome activation drives breast cancer progression.

Prospective study of the dietary inflammatory index and risk of breast cancer in postmenopausal women. Food Res. Article CAS Google Scholar. Harmon, B. The dietary inflammatory index is associated with colorectal cancer risk in the multiethnic cohort. CAS PubMed PubMed Central Google Scholar.

Hodge, A. Dietary inflammatory index, Mediterranean diet score, and lung cancer: a prospective study. Cancer Causes Control 27 , — Steck, S. Index-based dietary patterns and colorectal cancer risk: a systematic review. Mocellin, S. Vitamin B6 and cancer risk: a field synopsis and meta-analysis.

Cancer Inst. Aranda, F. Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer. Oncogene 34 , — Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep. Goodwin, P. Prognostic effects of hydroxyvitamin D levels in early breast cancer. Tretli, S.

Association between serum 25 OH D and death from prostate cancer. Cancer , — Dou, R. Vitamin D and colorectal cancer: molecular, epidemiological and clinical evidence.

Song, M. Plasma hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut 65 , — This work provides the first evidence of an inverse correlation between levels of hydroxyvitamin D and colorectal cancer risk, according to the degree of lymphocyte infiltration in the tumor bed.

Giangreco, A. Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,dihydroxyvitamin D in men with prostate cancer and an in vitro model.

Steroid Biochem. Batai, K. Vitamin D and immune response: implications for prostate cancer in African Americans. Cao, Y. Regular aspirin use associates with lower risk of colorectal cancers with low numbers of tumor-infiltrating lymphocytes.

Gastroenterology , — e4 Bruce, D. Intrinsic requirement for the vitamin D receptor in the development of CD8αα-expressing T cells. Larriba, M. PLoS One 6 , e Protiva, P. Calcium and 1,dihydroxyvitamin D3 modulate genes of immune and inflammatory pathways in the human colon: a human crossover trial.

Buck, K. Serum enterolactone and prognosis of postmenopausal breast cancer. Hallund, J. The effect of a lignan complex isolated from flaxseed on inflammation markers in healthy postmenopausal women.

Eisenberg, T. Cardioprotection and lifespan extension by the natural polyamine spermidine. Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer Cell 30 , — This paper demonstrates that caloric-restriction mimetics are as efficient as fasting in stimulating an autophagy-dependent anticancer immune response.

Furman, D. Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. Coffee induces autophagy in vivo. Cell Cycle 13 , — Alicandro, G. Coffee and cancer risk: a summary overview.

Cancer Prev. Alisson-Silva, F. Human risk of diseases associated with red meat intake: analysis of current theories and proposed role for metabolic incorporation of a non-human sialic acid. Aspects Med.

Bao, Y. Association of nut consumption with total and cause-specific mortality. This work demonstrates a significant and intriguing inverse correlation between nut consumption and cancer-induced mortality.

Bonaccio, M. Nut consumption is inversely associated with both cancer and total mortality in a Mediterranean population: prospective results from the Moli-sani study. Siri-Tarino, P. Saturated fats versus polyunsaturated fats versus carbohydrates for cardiovascular disease prevention and treatment.

Flint, T. Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity. This work elucidates how tumor-driven IL-6 production subverts the immunostimulatory effects induced by fasting and a ketogenic diet, thereby limiting anticancer immunity.

Sjöström, L. Effects of bariatric surgery on cancer incidence in obese patients in Sweden Swedish Obese Subjects Study : a prospective, controlled intervention trial.

Lancet Oncol. Rossi, E. Obesity-associated alterations in inflammation, epigenetics, and mammary tumor growth persist in formerly obese mice. Lee, C. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Di Biase, S. Fasting-mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity.

Cheng, C. Fasting-mimicking diet promotes Ngn3-driven beta-cell regeneration to reverse diabetes. Kreso, A. Evolution of the cancer stem cell model. Cell Stem Cell 14 , — Madeo, F. Caloric restriction mimetics: towards a molecular definition.

Drug Discov. Klement, R. Anti-tumor effects of ketogenic diets in mice: a meta-analysis. PLoS One 11 , e Woolf, E. Tumor metabolism, the ketogenic diet and β-hydroxybutyrate: novel approaches to adjuvant brain tumor therapy.

Lussier, D. Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet. BMC Cancer 16 , Husain, Z. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells.

Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers.

Chen, A. A Phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. Zhang, H. This pioneering paper reveals the antisenescence effects of NAD in a mammalian model of aging.

Download references. is supported by the Ligue contre le Cancer Équipe Labelisée ; Agence National de la Recherche ANR —Projets Blancs; ANR, under the framework of E-Rare-2, ERA-Net for Research on Rare Diseases; Association pour la Recherche sur le Cancer ARC ; Cancéropôle Ile-de-France; Institut National du Cancer INCa ; Institut Universitaire de France; Fondation pour la Recherche Médicale FRM ; European Commission ArtForce ; European Research Council ERC ; LeDucq Foundation; LabEx Immuno-Oncology; RHU Torino Lumière, SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination SOCRATE ; SIRIC Cancer Research and Personalized Medicine CARPEM ; and Paris Alliance of Cancer Research Institutes PACRI.

Faculty of Medicine, University of Paris Sud, Kremlin-Bicêtre, France. Center of Clinical Investigations in Biotherapies of Cancer CICBT , Villejuif, France. INSERM U, Gustave Roussy Cancer Campus, Villejuif, France. Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

Équipe 11 Labellisée Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. Institut National de la Santé et de la Recherche Médicale, U, Paris, France.

Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France. Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France. You can also search for this author in PubMed Google Scholar. Correspondence to Laurence Zitvogel or Guido Kroemer. Reprints and permissions.

Nutrition, inflammation and cancer. Nat Immunol 18 , — Download citation. Received : 27 March Accepted : 26 April Published : 19 July Issue Date : 01 August Anyone you share the following link with will be able to read this content:.

Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. International Journal of Clinical Oncology Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Skip to main content Thank you for visiting nature. nature nature immunology review articles article. Download PDF. Subjects Cancer Immunosurveillance Inflammation Tumour immunology. Abstract Quantitative and qualitative aspects of nutrition have a profound effect on leukocytes and thereby affect proinflammatory carcinogenic effects or anticancer immune responses.

A framework for examining how diet impacts tumour metabolism Article 17 September Developing dietary interventions as therapy for cancer Article 25 May The gut microbiome: what the oncologist ought to know Article Open access 14 July Main People with cancer often rationalize their disease as being a consequence of adverse life experiences; however, large population studies have not established such a correlation 1.

Figure 1: Relationships among nutrition, inflammation and immunity, and cancer. Full size image. Figure 2: Pathophysiological mechanisms that link nutrition to carcinogenesis, aging and resistance to chemotherapy.

Figure 3: Immune-system-mediated effects of fasting and caloric-restriction mimetics in anticancer therapy. Figure 4: Immune-system-mediated anticancer effects of dietary vitamin B6 and vitamin D3. Additional information Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Similar content being viewed by others. References Schoemaker, M. Article PubMed PubMed Central Google Scholar Font-Burgada, J. Article CAS PubMed Google Scholar Stringhini, S. Article PubMed PubMed Central Google Scholar Deng, T.

Article CAS PubMed Google Scholar Tomasetti, C. Article CAS PubMed PubMed Central Google Scholar Tomasetti, C. Article CAS PubMed PubMed Central Google Scholar López-Otín, C. Article CAS PubMed Google Scholar Koene, R.

Article PubMed PubMed Central Google Scholar Hullar, M. Article CAS PubMed PubMed Central Google Scholar O'Keefe, S. Article CAS PubMed PubMed Central Google Scholar Schäfer, M. Article CAS PubMed Google Scholar Palucka, A. Article CAS PubMed PubMed Central Google Scholar Zitvogel, L.

Article CAS PubMed Google Scholar Karki, R. Article CAS PubMed PubMed Central Google Scholar Nathan, C. Article CAS PubMed PubMed Central Google Scholar Elliott, L. Article CAS PubMed PubMed Central Google Scholar Chen, W.

Article CAS PubMed Google Scholar Mittal, D. Article CAS PubMed Google Scholar Galluzzi, L. Article CAS PubMed Google Scholar Krysko, D. Article CAS PubMed Google Scholar Sharma, P. Article CAS PubMed PubMed Central Google Scholar Pitt, J. Article CAS PubMed Google Scholar Bindea, G.

Article CAS PubMed Google Scholar Tirosh, I. Article CAS PubMed PubMed Central Google Scholar Bougherara, H. Article PubMed PubMed Central Google Scholar Vacchelli, E.

Article CAS PubMed Google Scholar Shivappa, N. Article PubMed Google Scholar Prieto, I. Article CAS PubMed PubMed Central Google Scholar Louis, P. Article CAS PubMed Google Scholar Pal, D.

Article CAS PubMed Google Scholar Mariño, G. Article CAS PubMed Google Scholar Pietrocola, F. Article CAS PubMed Google Scholar Yang, L.

Article CAS PubMed PubMed Central Google Scholar Umemura, A. Article CAS PubMed PubMed Central Google Scholar Zhong, Z. Article CAS PubMed PubMed Central Google Scholar Doerner, S.

Article CAS PubMed PubMed Central Google Scholar Klevorn, L. Article CAS PubMed PubMed Central Google Scholar Lamas, O. Article PubMed Google Scholar Yang, H. Article CAS PubMed PubMed Central Google Scholar Macia, L.

Article CAS PubMed Google Scholar Conroy, M. Article PubMed Google Scholar James, B. Article CAS PubMed Google Scholar Mirsoian, A. Article PubMed PubMed Central Google Scholar Traba, J.

Article PubMed PubMed Central Google Scholar Pietrocola, F. Article CAS PubMed PubMed Central Google Scholar Wang, A. Article CAS PubMed PubMed Central Google Scholar Dror, E. Article CAS PubMed Google Scholar van Niekerk, G. Article CAS PubMed PubMed Central Google Scholar Puchalska, P.

Article CAS PubMed PubMed Central Google Scholar Youm, Y. Article CAS PubMed PubMed Central Google Scholar Hopkins, B. Article CAS PubMed PubMed Central Google Scholar Moore, L. Article CAS PubMed PubMed Central Google Scholar Iyengar, N. Article CAS PubMed Google Scholar Kolb, R. Article CAS PubMed PubMed Central Google Scholar Shivappa, N.

Article CAS Google Scholar Harmon, B. CAS PubMed PubMed Central Google Scholar Hodge, A. Article CAS PubMed PubMed Central Google Scholar Steck, S. Article CAS PubMed PubMed Central Google Scholar Mocellin, S. Article CAS PubMed Google Scholar Aranda, F. Article CAS PubMed Google Scholar Goodwin, P.

Article CAS PubMed Google Scholar Tretli, S. Article CAS PubMed PubMed Central Google Scholar Dou, R. Article CAS PubMed PubMed Central Google Scholar Song, M. Article CAS PubMed Google Scholar Giangreco, A. Article CAS PubMed Google Scholar Batai, K. Article CAS PubMed PubMed Central Google Scholar Cao, Y.

Article CAS PubMed Google Scholar Bruce, D. Article CAS PubMed Google Scholar Larriba, M. Article CAS PubMed PubMed Central Google Scholar Protiva, P. Article CAS PubMed PubMed Central Google Scholar Buck, K.

Article CAS PubMed Google Scholar Hallund, J. Article CAS PubMed Google Scholar Eisenberg, T. Article CAS PubMed PubMed Central Google Scholar Pietrocola, F.

Article CAS PubMed PubMed Central Google Scholar Furman, D. Article CAS PubMed PubMed Central Google Scholar Alicandro, G.

Article CAS PubMed PubMed Central Google Scholar Bao, Y. Article CAS PubMed PubMed Central Google Scholar Bonaccio, M. Article CAS PubMed Google Scholar Siri-Tarino, P. Article CAS PubMed PubMed Central Google Scholar Flint, T. Article CAS PubMed PubMed Central Google Scholar Sjöström, L.

Article PubMed Google Scholar Rossi, E. Article CAS Google Scholar Lee, C. Article PubMed PubMed Central Google Scholar Di Biase, S. Article CAS PubMed PubMed Central Google Scholar Cheng, C. Article CAS PubMed PubMed Central Google Scholar Kreso, A.

Article CAS PubMed Google Scholar Madeo, F. Article CAS PubMed Google Scholar Klement, R. Article CAS PubMed PubMed Central Google Scholar Woolf, E. Article CAS PubMed PubMed Central Google Scholar Lussier, D. Article CAS PubMed PubMed Central Google Scholar Husain, Z. Article CAS PubMed Google Scholar Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group.

Article CAS PubMed Google Scholar Zhang, H. Article CAS PubMed Google Scholar Download references. Acknowledgements G. View author publications.

Ethics declarations Competing interests L. and G. are founders of the biotechnology company EverImmune. Rights and permissions Reprints and permissions.

About this article. Cite this article Zitvogel, L. Copy to clipboard. Publish with us Submission Guidelines For Reviewers Language editing services Submit manuscript. Search Search articles by subject, keyword or author. Show results from All journals This journal.

Advanced search. Close banner Close. Email address Sign up. I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer.